See every side of every news story
Published loading...Updated

#Vera Therapeutics Secures Exclusive License for Revolutionary B Cell Fusion Protein from Stanford University Amidst Growth Surge

Summary by csimarket.com
BRISBANE, Calif. Jan. 13, 2025 ' Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology firm dedicated to developing transformative treatments for serious immunological diseases, has made a significant leap forward in its research portfolio. The company announced today that it has entered into an exclusive licensing agreement with Stanford University for VT-109, an innovative next-generation fusion protein designed to target…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

csimarket.com broke the news in on Saturday, January 25, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.